Ergomed Share Chat (ERGO)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ergomed	LSE:ERGO	London	Ordinary Share	GB00BN7ZCY67	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-1.00p	-0.54%	184.00p	181.00p	187.00p	185.00p	184.00p	185.00p	2,703	11:13:30

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	39.2	0.3	1.3	141.5	73.10

Ergomed Share Discussion Threads

Showing 176 to 199 of 200 messages

Chat Pages: 8 7 6 5 4 3 2 1

Date	Subject	Author	Discuss
28/9/2017 22:24	I was only offered a very small allocation (<200 shares), so opted not to participate as broker costs are relatively high for purchases of that size.	timbo003	Read Full Thread Reply
28/9/2017 18:17	hxxps://www.equitydevelopment.co.uk/edreader/?d=%3D%3DAM0MjM Ergomed plc Outlook focused on PeproStat data soon H1 performance was in line with expectations . Looking out, the early completion of recruitment into the Pepro Stat Haemostatix trial means the read out is expected in Q4 2017 , substantially ahead of schedule. The valuation range remains unchanged at 232p - 397p and the business remain s on track to match expectations of significant growth	douglas fir	Read Full Thread Reply
28/9/2017 13:31	Notice Peter George managed to get his hands on £75 k's worth	bermudashorts	Read Full Thread Reply
28/9/2017 11:01	Book build ended quickly - none available	piedro	Read Full Thread Reply
28/9/2017 09:20	Timbo - It's actually a fairly small placing and a great price so would assume it will be oversubscribed. Good luck - hope you get some.	bermudashorts	Read Full Thread Reply
28/9/2017 08:58	News flow order is beginning to make sense, looks like they couldn't get a US based PV business at the right price (at least for now), Have gone for a top up in the book build at 165p, will let you know how I get on	timbo003	Read Full Thread Reply
27/9/2017 10:32	happy holder here. back to 200p then onto 250p hopefully where share price may consolidate for a while. NED bought 100,000 shares at 190p on 03.04.17.	mfhmfh	Read Full Thread Reply
27/9/2017 07:51	Timbo, that was my first reaction too, as posted on lse. Good stuff!	bermudashorts	Read Full Thread Reply
27/9/2017 07:41	Signing a deal like that,just days before the initial read out from the Haemostatix trial must bode well for the trial results which are due by the end of this week (I think). Does someone know something about the trial outcome, why sign now, why not wait?	timbo003	Read Full Thread Reply
27/9/2017 07:27	Excellent news. Very encouraging to sign deals while still in phase 2.	santar	Read Full Thread Reply
19/9/2017 15:45	Have high expectations of the PeproStat results - hope they are well founded!	bermudashorts	Read Full Thread Reply
19/9/2017 15:24	Numis today reiterates 275p target price	mfhmfh	Read Full Thread Reply
19/9/2017 14:02	Webinar after results was upbeat - will post link when recording is public	edmonda	Read Full Thread Reply
15/9/2017 09:17	Results out on Monday and for anyone wanting to see new CEO and Stephen present there is a webinar with Q&A on next day : at 12.45, Tuesday 19th. Just register here: https://register.gotowebinar.com/register/794515183261947906	edmonda	Read Full Thread Reply
14/8/2017 13:10	FDA have finally lifted their hold on Cel-Sci's Multikine trial https://investegate.co.uk/ergomed-plc--ergo-/rns/fda-removal-of-hold-on-ph3-trial-with-multikine/201708141231019319N/	bermudashorts	Read Full Thread Reply
03/8/2017 20:52	They seem quite close to some $	greg the grinch	Read Full Thread Reply
03/8/2017 20:51	What do people think of the Haemostatix competition?	greg the grinch	Read Full Thread Reply
31/7/2017 12:21	Interesting hxxps://endpts.com/labcorp-nabs-chiltern-booting-its-big-covance-cro-group-to-20k-plus-staffers-in-1-2b-deal/?utm_medium=email&utm_campaign=Monday%20-%20July%2031%202017&utm_content=Monday%20-%20July%2031%202017+CID_64469a6d006a6b3f7e39f9be4a77ae77&;utm_source=ENDPOINTS%20emails&utm_term=LabCorp%20nabs%20Chiltern%20booting%20its%20big%20Covance%20CRO%20group%20to%2020K-plus%20staffers%20in%2012B%20deal	bermudashorts	Read Full Thread Reply
24/7/2017 10:06	PeproStat trial now fully recruited - that was quick! It was only a month ago that we were advised they had recruited half of the patients. Good stuff and now look forward to results in Q4. hTtps://www.investegate.co.uk/ergomed-plc--ergo-/rns/recruitment-complete-early-for-phase-iib-study/201707240700068231L/	bermudashorts	Read Full Thread Reply
19/7/2017 07:37	Thanks - quite like the thought of a couple of II's keeping the BOD on their toes. If they hope to complete on the acquisition of a US PV by September, they must presumably have already identified the company and be some way down the line in the process. By the way, great information in your final paragraph re. Haemostatix - sounds very promising.	bermudashorts	Read Full Thread Reply
19/7/2017 06:36	Yes BS, that was the reason given, I assume there wasn't any mention of technology/ product acquisitions in the AIM admission document, but I haven't checked. ( http://www.ergomedplc.com/wp-content/uploads/2014/07/Ergomed-Admission-Document.pdf ) Apparently it was the same two institutions who voted against the disapplication rights (forcing the Poll) at the AGM.	timbo003	Read Full Thread Reply
18/7/2017 23:32	Thanks Timbo. Did he say why some institutional investors were upset with the Haemostatix acquisition? Presumably, not in keeping with strategy?	bermudashorts	Read Full Thread Reply
18/7/2017 23:09	Notes from ShareSoc investor meeting 12th July 2017 Stephen Stamp (CFO) gave the presentation The presentation slides can be found here: https://tinyurl.com/yallezrg There was not much new in the slides and as usual at these sort of events, most of the insights came from the Q&A session which followed the presentation, see notes below (Note: all questions and answers are paraphrased, they do not represent a verbatim account) Q: At previous investor meetings you have stated that Ergomed will look to acquire a US Pharmaco Vigilance (PV) business if the price is right, is this still an aspiration, are you going to have to compete against other wannabe buyers? A: We would hope to complete an acquisition by September. There has been growing interest from private equity in PV businesses probably due to their cash generative nature. Q: Do intend to do another technology acquisition like Haemostatix? A: Some of our institutional investors were upset by the Haemostatix acquisition, we do not intend to do another one Q: Why don’t you do concentrate on smaller clinicals for your co-development model, this was you could do more and spread the risk? A: That is our intention, we wouldn’t embark on another study the size (and duration) of the Cel-Sci Head and Neck Cancer study. Instead we would do 3 or 4 smaller (and faster) co-development studies. A: When do you expect the readout for the Cel-Sci study? Q: The study will complete (and then report) when mortality reaches a certain number of patients, this will probably be in around two years time. Q: What successes have you had with the co-development model? A: We received a US$2m milestone payment from Genzyme from the tasidotin co-development (this was pre-IPO, see Aim admission document) and also the recent completed Lorediplon study. Q: Can you tell us more about Lorediplon? A: Ferrer are developing Lorediplon for insomnia, the recently conducted phase II study was a big success with results indicating a suitable duration of action and no appreciable hangover effect Q: How much of as discount to you give for the co-development clinicals? A: 30 – 50% reduction in the fees in exchange for a small royalty and a share in any milestone payments if the drug is outlicenced Q: How much Revenue has Ergomed forgone in the last three years as a result of applying a discount to the co-development studies? A: £3.7m (2016), £3.5m (2015), £3.0m (2014) Q: How much revenue has been foregone as a result of the Cel-Sci study? A: £7m Q: How do you identify co-development opportunities? A: Most of the leads come from partnering conferences, AM might do 12 meetings a day with potential co-development partners at these conferences. We then use an expert panel to screen potential opportunities. The objective is to end up with 2 new opportunities/year. Q: The two Companies (3-D Matrix and Arch therapeutics) developing coagulant products based on self-assembly peptides (SAPs) which will be competitors to the Haemostatix products, both appear to claim their products will be suitable for use with commonly used anticoagulants. Will Ready flow and Peprostat also be suitable for use with anticoagulants? (see AGM notes for more background on SAPs: http://uk.advfn.com/cmn/fbb/thread.php3?id=32307946&from=164#firstpost ) A: SS ducked this question and said he would refer it back to Andrew Mackie. AM has since confirmed by email that anticoagulants should not interfere and there is good animal and human data to support this, furthermore the Haemostatix technology may offer an advantage over the SAPs, as the SAPs appear to work by forming a barrier over the wound that then allows the body’s coagulation system to form the blood clot behind the SAPs. The Haemostatix products form the blood clot directly by introducing a small amount of peptide which then promotes the clot via endogenous fibrinogen.	timbo003	Read Full Thread Reply
13/7/2017 13:44	Look forward to it. Sounds promising and good to see so many HNW's there - hope they left reaching into their very deep pockets for their wallets!	bermudashorts	Read Full Thread Reply

Chat Pages: 8 7 6 5 4 3 2 1

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.